In patients with end-stage liver disease (ESLD), the definitive treatment is a liver transplant. In the United States, the most common indication for liver transplantation is hepatitis C followed by alcoholic liver disease. Immunosuppression is indicated post-implantation and the most common complications are rejection and infection.

Introduction to Liver Transplantation
Orthotopic liver transplantation encompasses the excision of the native liver, along with the portal vein, hepatic artery and common bile duct and parts of the inferior and superior vena cava. A donor liver is implanted at the same site and anastomosed to the different vessels and into the bile duct. Liver transplantation is becoming a common procedure for ESLD, and patients with hepatitis C and alcoholic liver disease make the majority of liver transplants recipients.

Definition of Liver Transplantation

Liver transplantation/ hepatic transplantation is the replacement of the diseased liver with a healthy liver from another person (allograft).

Epidemiology of ESLD

Approximately, six thousand liver transplants are performed per year in the United States. In 2014, 7,200 liver transplants were performed in the united states with 330 of these involving livers from live patients. This number does not meet the current waiting list of 15,850 patients with ESLD who are candidates for liver transplantation. Currently, ESLD is reported to be responsible for 9.4 deaths per 100,000 persons but this is an under-estimation as cases with acute (fulminant) hepatitis are not included in this figure. The 5-year survival rate after liver transplantation is 72%.

Indications for Liver Transplantation
Liver transplant is the treatment option for patients with liver failure whom no other form of therapy is considered effective and also for the treatment of some people with liver cancer.

Malignancies of the liver or biliary system, idiopathic liver disease, autoimmune disease, primary biliary cirrhosis, and primary sclerosing cholangitis can also lead to ESLD, or be associated with liver cirrhosis and eventually necessitate a liver transplant. Less common causes of ESLD that could need liver transplantation include inborn errors of metabolisms, acute liver failure, and the hepatitis B virus.

Medical Therapy Before Liver Transplantation

Patients who will undergo a liver transplantation procedure should be medically managed before the implantation to lower the risk of post-operative complications. This medical management involves managing ESLD complications, such as encephalopathy, ascites, spontaneous bacterial peritonitis, and active viral hepatitis.

Clinical Presentation of Patients Needing a Liver Transplant

Patients with ESLD who present with recurrent variceal hemorrhage due to portal hypertension, intractable ascites, spontaneous bacterial peritonitis that is recurrent and medically refractory encephalopathy, should be evaluated for possible liver transplantation. Additionally, any patient with fulminant hepatic failure that is life-threatening should be considered for liver transplantation. The decision to go for liver transplantation can also be based on a decreased quality of life that is intolerable by the patient and not on life-threatening complications alone.

Relevant Anatomy for Liver Transplantation

The liver can be divided into two main lobes, right and left by a line running through the gallbladder fossa in the major fissure.
The diseased liver should be excised and the donor liver, usually with parts of the bile duct from the donor, is implanted in place of the former one.

Recent advances have put forward the segmental anatomy of the liver where the liver is divided into 8 couinaud segments. Each segment has its own vascular inflow, vascular outflow, and independent biliary tract drainage and thus can be excised and replaced independently during segmental transplantation.

Furthermore, liver transplantation is a complex surgery with numerous variables in the form of 4 anastomoses:

- Arterial anastomosis
- Venous inflow anastomosis (portal venous system)
- Venous outflow anastomosis (hepatic vein and/or inferior vena cava)
- Biliary anastomosis

The bile duct is anastomosed to the recipient’s bile duct or through a **choledochojejunostomy**. A T-tube should be inserted in the bile duct to confirm its patency in the coming weeks, and to confirm that the new liver is functioning properly by secreting bile.

**Immunosuppression Post-Liver Transplantation**

After liver transplantation, it is important to guarantee both the survival of the transplant and the patient which is achieved by **immunosuppression**. Different regimens can be used but maintenance is usually with **cyclosporine, azathioprine, and prednisone**.

The first step is to lower the risk of acute rejection by **induction therapy**. Induction therapy at the time of the transplant includes high-dose corticosteroids and anti-thymocyte globulin. Tacrolimus, a T-cell proliferation inhibitor, and mycophenolate can be also used as induction therapy.

More recently, it was shown that **dual therapy with steroids and calcineurin inhibitors**, such as cyclosporine, also works. Additionally, some centers taper-off steroids eventually and the patient ends up on monotherapy with cyclosporine with very little increase in the risk of graft rejection.

In addition to immunosuppression, prophylactic antibiotics have to be administered such as septrin for respiratory infections, acyclovir for hepatic infections and nystatin drops for
Post-Transplant Complications

The most common complication after liver transplantation is **acute graft rejection** which can happen in up to 70% of the cases and usually in the first two weeks post-transplant. Patients present with jaundice, high bilirubin, and alkaline phosphatase levels and the patient could have liver tenderness.

**High-dose prednisolone or methylprednisolone** is the treatment of choice for acute transplant rejection. Fortunately, this regimen is effective in up to 80% of the cases. Less commonly, in 5% of the patients, **chronic rejection** could happen. In these patients, the usual presentation is a gradual increase in bilirubin and alkaline phosphatase. A liver biopsy would show **occlusion of the small bile ducts**.

**Post-transplant infections** are also common in the first month due to severe immunosuppression during this period and bacterial and fungal infections are common. Patients present with **cholangitis**, or an abdominal abscess, and complain of fever, abdominal pain or are asymptomatic.

After six months of transplantation, the risk of infection becomes similar to the general population. **Cytomegalovirus infection** is common in the first three months after liver transplantation and treatment includes ganciclovir IV for 2 to 4 weeks. The risk of **malignancy** increases with immunosuppression, especially lymphomas and squamous cell carcinoma.

Diagnostic workup for patients with post-transplant complications

Patients who are liver transplant recipients and who present with jaundice, fever, abdominal pain, elevated bilirubin and high alkaline phosphatase are suspected to have liver transplant rejection and should be evaluated and monitored closely. Laboratory investigations include **serum bilirubin** and **liver function tests** to evaluate the synthetic and secretory function of the liver. **Evaluation of bile secretion in the T-tube bile duct stent** should also be attempted.

Due to the similarity in symptoms between rejection and infection, **blood cultures** are indicated to exclude infectious complications. Patients with liver transplantation are immunosuppressed and are at risk of developing opportunistic infections such as **pneumocystis carinii pneumonia** (PCP), **cytomegalovirus infection** and **candida infestations**, and they should be evaluated for that.

A **chest x-ray** to exclude PCP, and an **abdominal CT scan** and **ultrasonography** to exclude intra-abdominal abscesses are indicated.

References

[Liver Transplants](https://www.medscape.com) via medscape.com

[Liver Transplantation Treatment & Management](https://www.medscape.com) via medscape.com

**Legal Note:** Unless otherwise stated, all rights reserved by Lecturio GmbH. For further legal regulations see our [legal information page](https://www.lecturio.com).